ATLAS 2026
Mapping the future of advanced therapies
From ex vivo foundations to emerging in vivo frontiers
Advanced therapies are at an inflection point. Programs built on advanced ex vivo platforms are now intersecting with rapidly emerging in vivo approaches, driven by progress in targeted delivery, gene expression control, genome editing, and immunology.
The Advanced Therapies Leadership & Acceleration Summit (ATLAS) will examine how innovation across ex vivo and in vivo strategies is redefining the relationship between biology and manufacturing. Bringing together senior scientific and strategy leaders, the summit will explore how scientific progress translates into CMC readiness, robust platforms, and scalable pathways from pre-clinical to commercial success.
Date
November 9, 2026 | Tour to Cytiva Customer Experience Center
November 10, 2026 | Presentations and networking
Event location
MassBio
700 Technology Square, 5th floor
Cambridge, MA 02139
Day 1 optional tour
November 9, 2026
Join us for an exclusive visit to Cytiva's Customer Experience Center in Marlborough, MA. Attendees will enjoy complimentary coach transportation from MassBio to the Customer Experience Center and back, making it easy to take part in this unique experience. Explore innovative technologies through hands-on demonstrations, engage with Cytiva specialists, and connect with industry peers in an interactive learning environment before the summit begins.
Note: Space is limited, so we recommend registering early to guarantee your spot
Day 1 tour schedule
November 9, 2026
| Time | Session |
|---|---|
| 09:30–10:00 | Arrive at MassBio, collect badges, coffee and tea, assemble for transport |
| 10:00–10:45 | Bus departs promptly, travel to Customer Experience Center |
| 10:45–11:45 | Tour |
| 11:45–12:45 | Lunch and netwoking |
| 12:45–1:45 | Tour continued |
| 1:45–2:45 | Return via bus to MassBio |
Day 2 highlights
ATLAS 2026 will explore:
-
Advances in biological control
Targeted delivery, expression regulation, genome editing, and immune and host interactions
-
Next-generation advanced therapy strategies
Emerging scientific approaches enabling greater precision, durability, and in vivo potential
-
Manufacturing readiness at scale
CMC innovations supporting larger indications, accelerated cell therapy processes, and robust manufacturing models
-
Platforms and analytics
Evolving platform strategies and advanced analytical approaches for managing increasing process and regulatory complexity
Day 2 general session
November 10, 2026
All times are listed in EST
| Time | Session |
|---|---|
| 09:30–10:00 | Registration opens, badge collection, networking |
| 10:00–10:15 | Welcome address - Vincent Guercio, Cytiva |
| 10:15–11:00 | Keynote address |
| 11:00–11:30 | From potency to scale: an integrated 1-day, non-activated CAR T platform - Saba Ghassemi, UPenn |
| 11:30–12:00 | Beyond the blood: CAR-T's solid ambition. - Cheng Liu, Eureka Therapeutics |
| 12:00–1:00 | Networking lunch and product showcase |
| 1:00–1:30 | Breakthroughs in viral vectors - Aravind Asokan, Duke University |
| 1:30–2:00 | Non-viral approaches for in vivo CAR-T - Jagesh Shah, Mirai Bio |
| 2:00–2:30 | LVV-based in vivo CAR-T - Speaker announced soon |
| 2:30–3:00 | LNP-based in vivo CAR-T - Daniel Getts, CREATE Medicines |
| 3:00–3:30 | Coffee break and networking |
| 3:30–4:45 | Panel discussion |
| 4:45–5:00 | Closing remarks: The road ahead and future outlooks |
| 5:00–7:00 | Networking cocktail reception |
Meet our speakers
Saba Ghassemi
Assistant Pro of Pathology and Laboratory Medicine at UPenn
Dr. Saba Ghassemi is an Assistant Professor of Pathology and Laboratory Medicine at the Perelman School of Medicine and Principal Investigator in the Center for Cellular Immunotherapies at the University of Pennsylvania. Her research combines engineering and T cell immunology to advance next-generation CAR T-cell therapies. She is recognized for pioneering rapid CAR T-cell manufacturing approaches designed to improve therapeutic performance, streamline production, and expand patient access to cellular immunotherapies.
Cheng Liu
Chief Executive Officer at Eureka Therapeutics
Dr. Cheng Liu is Founder and CEO of Eureka Therapeutics, a clinical-stage biotechnology company focused on developing innovative cellular immunotherapies for cancer treatment. A recognized pioneer in T cell engineering and immunotherapy, Dr. Liu has dedicated his career to advancing next-generation cancer therapies. He is a widely published scientist, with research appearing in leading journals including Science and Nature, and is editor of a leading reference book on biosimilar monoclonal antibody development.
Jagesh Shah
Chief Scientific Officer at Mirai Bio
Jagesh Shah is Chief Scientific Officer at Mirai Bio, where he applies expertise in quantitative biology, biophysics, and systems biology to advance in vivo delivery technologies for novel therapeutics. Prior to Mirai, he held leadership roles at Sana Biotechnology, Flagship Pioneering, and Cobalt Biomedicine. Earlier in his career, he spent more than a decade on the faculty of Harvard Medical School and Brigham and Women's Hospital leading systems biology research.
Aravind Asokan
Professor & Director of Gene Therapy, Department of Surgery, School of Medicine at Duke University
Dr. Aravind Asokan is a research and innovation leader focused on advancing genetic and cellular medicines from discovery through clinical translation. At Duke University, he directs a research program spanning AAV vectors, RNA platforms, and gene therapies. He has co-founded multiple biotechnology organizations dedicated to translating gene therapy platforms to the clinic and serves on the scientific advisory boards of several clinical-stage biotech companies. He was named a Fellow of the National Academy of Inventors in 2025.
Daniel Getts
Daniel Getts is a global leader in RNA therapeutics and immune engineering and founder and CEO of CREATE Medicines, a clinical-stage biotech pioneering in vivo mRNA immune cell programming. A serial biotechnology entrepreneur, he has helped advance 11 novel therapies into clinical trials across cancer, autoimmune disease and transplant rejection. Getts holds more than 200 patents and has published extensively in leading peer-reviewed journals.
Fill out the form below to register for our event!
Want to keep learning? Select your preferences to get more helpful content from Cytiva!
By clicking any of these options, you are agreeing to receive marketing emails, newsletters, and other promotional communications from Cytiva from time to time. You have a right to withdraw our consent at any time by clicking here. We may still continue to send you service-related and other non-promotional communications. For more information relating to our privacy practices, we invite you to review our Privacy policy.
By attending, you confirm you are not located in or a national of a sanctioned country or region, are not a restricted party, and acknowledge that this training may include content subject to U.S. and other export control and sanctions laws. Sharing the content, whether verbally, visually, electronically, or via screen-sharing during webinars must comply with these laws. Allowing unauthorized or restricted individuals to view or participate is a violation and may result in civil and/or criminal penalties.
Thank you for registering for ATLAS Boston from
November 9 – November 10, 2026
Your registration has been received.
Submission details
Date: November 9 - November 10, 2026
Location:
MassBio
700 Technology Square 5th floor, Cambridge, MA 02139, United States
You're all set
Check your inbox for your confirmation.
, you have been placed on a waiting list.
Check email for more information.
, thanks for letting us know.
Come visit is next time!